Prostate cancer: A dynamic illness with shifting targets

Lancet Oncology

Volumn 4, Issue 7, 2003, Pages 407-414

  Shaffer, David R ^a   Scher, Howard I ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANDROGEN RECEPTOR; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; ARF PROTEIN; ATRASENTAN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CETUXIMAB; ENDOTHELIN RECEPTOR ANTAGONIST; GEFITINIB; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; MITOXANTRONE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; SALICYLATE SODIUM; TEMSIROLIMUS; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; HUMAN; METASTASIS; MOLECULAR DYNAMICS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; STROMA CELL;

EID: 0038642308     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01138-0     Document Type: Review

References (77)

1. Huggins C, Hodges CV. Studies on prostatic cancer, effect of castration, of estrogen and of androgen injection on serum phosphates in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-97.
2. Feldman BJ, Feldman D. The development of androgen independent prostate cancer. Nature Rev Cancer 2001; 1: 34-45.
3. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001; 93: 1687-97.
4. Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 2002; 9: 61-73.
5. Isaacs JT, Coffey DS. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studied in the Dunning R-3327 H adenocarcinoma. Cancer Res 1981; 41: 5070-74.
6. Craft N, Chhor C, Tran C, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 1999; 59: 5030-36.
7. Bruchovsky N, Rennie PS, Coldman AJ, et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990; 50: 2275-82.
8. De Marzo AM, Nelson WG, Meeker AK, Coffey DS. Stem cell features of benign and malignant prostate epithelial cells. J Urol 1998; 160: 2381-92.
9. Bui M, Reiter RE. Stem cell genes in androgen-independent prostate cancer. Cancer Metastatis Rev 1998; 17: 391-99.
10. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999; 26: 263-73.
11. La Tulippe E, Satagopan J, Smith A, et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002; 62: 449-506.
12. Buchanan G, Greenberg NM, Scher HI, et al. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001; 7: 1273-81.
13. Scher HI, Kelly WK. The flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostatic cancer. J Clin Oncol 1993; 11: 1566-72.
14. Scher HI, Liebertz C, Kelly WK, et al. Bicalutamide for advanced prostate cancer: the natural vs. treated history of disease. J Clin Oncol 1997; 15: 2928-38.
15. Goldenberg SL, Bruchovsky N, Rennie PS, Coppin CM. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma. J Urol 1988; 138: 1460-65.
16. Keller ET, Zhang J, Cooper CR, et al. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 2001; 20: 333-49.
17. Labrie F, Dupont A, Belanger A, et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 1983; 4: 579-94.
18. Schmitt B, Bennett C, Seidenfeld J, et al. Maximal androgen blockade for advance prostate cancer (Cochrane Review). In: Cochrane Database Syst Rev 2000, Issue 2: CD001526.
19. Segnitz B, Gehring U. The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin. J Biol Chem 1997; 272: 18694-701.
20. Solit DB, Zheng FF, Drobnjak M, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002; 8: 986-93.
21. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 2002; 1: 111-21.
22. Eastham JA, Stapleton AM, Gousse AE, et al. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1995; 1: 1111-18.
23. Meyers FJ, Gumerlock PH, Chi SG, et al. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 1998; 83: 2534-39.
24. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-44.
25. Reed JC. Bcl-2 family proteins. Oncogene 1998; 17: 3225-36.
26. Eastham JA, Grafton W, Martin CM, Williams BJ. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. J Urol 2000; 164: 814-19.
27. Morris MJ, Scher HI. Novel strategies adn therapeutics for the treatment of prostate cancer. Cancer 2000; 89: 1329-48.
28. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56: 1253-55.
29. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999; 96: 4240-45.
30. Cairns P, Okami K, Halachmi S, et al. Frequent inactivition of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997; 57: 4997-5000.
31. Dong JT, Sipe TW, Hyytinen ER, et al. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene 1998; 17: 1979-82.
32. Feilotter H, Nagai M, Boag A, et al. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998; 16: 1743-49.
33. Gray IC, Stewart LM, Phillips SM, et al. Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancerd 1998; 78: 1296-300.
34. McMenamin ME, Soung P, Perera S, et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999; 59: 4291-96.
35. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10314-19.
36. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996; 274: 782-84.
37. Van Antwerp DJ, Martin SJ, Kafri T, et al. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996; 274: 787-89.
38. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274: 784-87.
39. Palayoor ST, Youmell MY, Calderwood SK, et al. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999; 18: 7389-94.
40. Herrmann JL, Beham AW, Sarkiss M, et al. Bcl-2 suppresses apoptosis resulting from disruption of the NF-kappa B survival pathway. Exp Cell Res 1997; 237: 101-09.
41. Muenchen HJ, Lin DL, Walsh MA, et al. Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor". Clin Cancer Res 2000; 6: 1969-77.
42. Kipp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994; 265: 956-59.
43. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 286-90.
44. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002; 7: 9-16.
45. Papandreou CN, Pagliaro L, Millikan RE, et al. Phase I study of PS-341, a novel proteasome inhibitor, in patients with advanced malignancies. Proc Am Soc Clin Onc 2000; 19 (Abstr 738).
46. Fossa SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase iii study of the european organization for research and treatment of cancer genitourinary group. J Clin Oncol 2001; 19: 62-71.
47. Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with how-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 7: 590-97.
48. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin. Oncol 1996; 14: 1756-64.
49. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
50. McEleny KR, Watson RW, Coffey RN, et al. Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate 2002; 51: 133-40.
51. Xing N, Qian J, Bostwick D, et al. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 2001; 48: 7-15.
52. Deveraux QL, Reed JC, IAP family proteins - suppressors of apoptosis. Genes Dev 1999; 13: 239-52.
53. Mesri M, Wall NR, Li J, et al. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001; 108: 981-90.
54. Sherwood ER, Van dongen JL, Wood CG, et al. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 1998; 77: 855-61.
55. Hayward SW, Cunha GR. The prostate: development and physiology. Radiol Clin North Am 2000; 38: 1-14.
56. Scher HI, Sarkis A, Reuter V, et al. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor-a in the progression of prostatic neoplams. Clin Cancer Res 1995; 1: 545-50.
57. Culing Z, Hobisch A, Cronauer MV, et al. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996; 28: 392-405.
58. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000; 44: 77-87.
59. Agus D, Akita R, Fox W, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2: 127.
60. Mendelsohn J, Dinney CP. The Willet F Whitmore Jr Lectureship: blockade of epidermal growth factor receptors as anticancer therapy. J Urol 2001; 165: 1152-57.
61. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 2000; 6: 4885-92.
62. Ferrara N. Vascular endothelial growth factor. Eur J Cancer 1996; 32: 2413-22.
63. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30336-43.
64. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000; 5 (suppl 1): 3-10.
65. Koeneman KS, Kao C, Ko SC, et al. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol 2000; 18: 102-10.
66. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001; 159: 2159-65.
67. Thalmann GN, Sikes RA, Devoll RE, et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 1999; 5: 2271-77.
68. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21: 679-89.
69. Scher H and Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 2000; 55: 323-37.
70. Kattan MW, Eastham JA, Stapleton AMF, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766-71.
71. Partin AW, Subong ENP, Walsh PC, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of lacalized prostate cancer: a multi-institutional update. JAMA 1997; 277: 1445-51.
72. D'Amico AV, Whittington R, Malkowicz SB, et al. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically prostate cancer. Urology 2000; 55: 572-77.
73. Cher ML, de Oliveira JG, Beaman AA, et al. Cellular proliferation and prevalence of micrometastic cells in the bone marrow of patients with clinically localized prostate cancer. Clin Cancer Res 1999; 5: 2421-25.
74. Olumi AF, Grossfeld GD, Hayward SW, et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59: 5002-11.
75. Sirotnak FM, She Y, Lee F, et al. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res 2002; 8: 3870-76.
76. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression to metastases and death from prostate cancer in men with PSA recurrence following radical prostatectomy. JAMA 1999; 281: 1591-97.
77. Agus DB, Cordon-Cardo C, Fox W, et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 1999; 91: 1869-76.